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Eukaryotic cells execute complex transcriptional pro-
grams in which specific loci throughout the genome
are regulated in distinct ways by targeted regulatory
assemblies. We have applied this principle to
generate synthetic CRISPR-based transcriptional
programs in yeast and human cells. By extending
guide RNAs to include effector protein recruitment
sites, we construct modular scaffold RNAs that
encode both target locus and regulatory action. Sets
of scaffold RNAs can be used to generate synthetic
multigene transcriptional programs in which some
genes are activated and others are repressed. We
apply this approach to flexibly redirect flux through
a complex branched metabolic pathway in yeast.
Moreover, these programs can be executed by
inducing expression of the dCas9 protein, which
acts as a single master regulatory control point.
CRISPR-associated RNA scaffolds provide a power-
ful way to construct synthetic gene expression pro-
grams for a wide range of applications, including
rewiring cell fatesor engineeringmetabolicpathways.
INTRODUCTION
Eukaryotic cells achieve many different states by executing
complex transcriptional programs that allow a single genome
to be interpreted in numerous, distinct ways. In these programs,
specific loci throughout the genome must be regulated indepen-
dently. For example, during development, it is often critical to
activate sets of genes associated with a new cell fate whilesimultaneously repressing sets of genes associated with a prior
or alternative fate. Similarly, environmental conditions often
trigger shifts in metabolic state, which requires activating a
new set of enzymes and repressing other previously expressed
enzymes, leading to new metabolic fluxes. These complex
multi-locus, multi-directional expression programs are encoded
largely by the pattern of transcriptional activators, repressors, or
other regulators that assemble at distinct sites in the genome.
Reprogramming these instructions to produce a different cell
type or state thus requires precisely targeted changes in gene
expression over a broad set of genes.
How might we engineer novel gene expression programs that
match the sophistication of natural programs? Such capabilities
would provide powerful tools to probe how changes in gene
expression programs lead to diverse cell types. These tools
would also provide the ability to engineer more sophisticated
designer cell types for therapeutic or biotechnological applica-
tions. Although a number of transcriptional engineering
platforms have been developed, there are major constraints for
constructing complex transcriptional programs. For example,
synthetic transcription factors (such as designed zinc fingers or
transcription activator-like [TAL] effectors) can target a specific
regulatory action to a key genomic locus, but it is challenging
to simultaneously target many loci in parallel because each
DNA-binding protein must be individually designed and tested
(Gaj et al., 2013). The bacterial type II CRISPR (clustered regu-
larly interspaced short palindromic repeats) interference system
(CRISPRi) provides an alternative suite of tools for genome regu-
lation (Qi et al., 2013). In particular, a catalytically inactive Cas9
(dCas9) protein, which lacks endonuclease activity, can be
used to flexibly target many loci in parallel by using Cas9-binding
guide RNAs that recognize target DNA sequences based only on
predictable Watson-Crick base pairing. CRISPRi regulation can
be used to achieve activation or repression by fusing dCas9 toCell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc. 339
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Figure 1. Genomic Regulatory Programming Using CRISPR and Multi-Domain Scaffolding RNAs
(A) lncRNAmoleculesmay act as scaffolds to physically assemble epigenetic modifiers at their genomic targets. Modular RNA structures can encode domains for
protein binding and DNA targeting to colocalize proteins to genomic loci.
(B) CRISPR RNA scaffold-based recruitment allows simultaneous regulation of independent gene targets. The minimal CRISPRi system silences target genes
when dCas9 and an sgRNA assemble to physically block transcription. Fusing dCas9 to transcriptional activators or repressors provides additional functionality.
When function is encoded in dCas9 (CRISPRi) or dCas9-effector fusion proteins, the sgRNA recruits the same function to every target site. To encode both target
and function in a scaffold RNA, sgRNAmolecules are extendedwith additional domains to recruit RNA-binding proteins that are fused to functional effectors. This
approach allows distinct types of regulation to be executed at individual target loci, thus allowing simultaneous activation and repression.activator or repressor modules (Gilbert et al., 2013; Mali et al.,
2013a), but these direct protein fusions are constrained to only
one direction of regulation. Thus, it remains challenging to engi-
neer regulatory programs in which many loci are targeted simul-
taneously but with distinct types of regulation at each locus.
To develop a platform for synthetic genome regulation that
allows locus-specific action, we took inspiration from natural
regulatory systems that encode both target specificity and regu-
latory function in the same molecule. In cell-signaling pathways,
scaffold proteins act to physically assemble interacting compo-
nents so that functional outcomes can be precisely controlled in
time and space (Good et al., 2011). Similar scaffolding principles
apply in genome organization, wherein, for example, long non-
coding RNA (lncRNA) molecules are proposed to act as assem-
bly scaffolds that recruit key epigenetic modifiers to specific
genomic loci (Figure 1A) (Rinn and Chang, 2012; Spitale et al.,340 Cell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc.2011). The idea that RNA can be used to coordinate biological
assemblies has important implications for engineering. RNA is
inherently modular and programmable: DNA targets can be
recognized by base pairing, and modular RNA-protein interac-
tion domains can be used to recruit specific proteins (Figure 1A).
The ability of engineered RNA scaffolds to coordinate functional
protein assemblies has already been elegantly demonstrated
(Delebecque et al., 2011).
To implement a synthetic, modular RNA-based system for
locus-specific transcriptional programming, we can extend the
CRISPR single-guide RNA (sgRNA) sequence with modular
RNA domains that recruit RNA-binding proteins. This approach
converts the sgRNA into a scaffold RNA (scRNA) that physically
links DNA binding and protein recruitment activities (Figure 1B).
Critically, a single scRNA molecule encodes both information
about the target locus and instructions about what regulatory
function to execute at that locus. This approach allows multidi-
rectional regulation (i.e., simultaneous activation and repression)
of different target genes as part of the same regulatory program.
Engineering multivalent RNA recruitment sites on each scRNA
offers the further possibility of independently tuning the strength
of activation or repression at each target site. The potential
viability of this approach is supported by a recent report showing
that a sgRNA extended with MS2 hairpins can recruit activators
to a reporter gene in human cells (Mali et al., 2013a).
Here, we demonstrate that CRISPR sgRNAs can be repur-
posed as scaffolding molecules to recruit transcriptional
activators or repressors, thus enabling flexible and parallel pro-
grammable locus-specific regulation. We use the budding yeast
S. cerevisiae as a testbed to identify three orthogonal RNA-pro-
tein binding modules and to optimize scRNA designs for single
and multivalent recruitment sites. We show that the system
developed in yeast also functions efficiently in human cells to
regulate reporter and endogenous target genes, and we extend
its scope to include recruitment of chromatin modifiers for gene
repression. We then demonstrate the use of CRISPR scaffold
RNAmolecules to construct synthetic multigene expression pro-
grams. Specifically, we are able to regulate multiple genes in a
highly branched biosynthetic pathway in yeast to express key
enzymes in alternative combinations. These synthetic transcrip-
tional programs, by combinatorially altering metabolic organi-
zation, allow us to flexibly redirect the pathway between five
distinct possible product output states. Finally, we show that
dCas9 can act as a master regulator of these gene expression
programs, receiving input signals and acting as a single control
point to execute a multigene response encompassing simulta-
neous activation and repression of downstream target genes.
RESULTS
CRISPR RNA Scaffolds Efficiently Activate Gene
Expression in Yeast
The minimal sgRNA previously used in CRISPR engineering
consists of several modular domains: a 20 nucleotide variable
DNA-targeting sequence and two structured RNA domains—
dCas9-binding and 30 tracrRNA—which are necessary for proper
structure formation and binding to Cas9 (Jinek et al., 2012; 2014;
Nishimasu et al., 2014). Here, to generate scaffold RNA (scRNA)
constructs with additional protein recruitment capabilities, we
first introduced a single RNA hairpin domain to the 30 end of
the sgRNA, connected by a two-base linker. For these recruit-
ment RNA modules, we used the well-characterized viral RNA
sequences MS2, PP7, and com, which are recognized by the
MCP, PCP, and Com RNA-binding proteins, respectively. We
fused the transcriptional activation domain VP64 to each of the
corresponding RNA-binding proteins.
We first tested the CRISPR scRNA platform in yeast. A strain
with a tet promoter driving a fluorescent protein reporter was
transformed to express dCas9, scRNAs targeting the tet oper-
ator, and the corresponding VP64 fusion proteins. We observed
significant reporter gene expression using each of the three
RNA-binding recruitment modules (Figure 2A). scRNA con-
structs with recruitment hairpin domains connected to the
sgRNA by linkers longer than two bases (up to 20 bases) gaveweaker reporter gene expression (Figure S1A available online).
scRNA designs with recruitment sequences attached to the 50
end of the sgRNA gave no significant activation (Figure S1B).
Northern blot analysis indicated that the 50 extended sequence
was degraded (Figure S2).
Gene activation mediated by scRNA recruitment of VP64 was
substantially greater than that for the direct dCas9-VP64 fusion
protein. Both MCP and PCP bind to their RNA targets as dimers
(Chao et al., 2008), which may account for some of the differ-
ence. The oligomerization state of the Com protein has not
been directly determined, but functional data consistent with a
monomer has been reported (Wulczyn and Kahmann, 1991).
Three RNA-Protein Recruitment Modules Act in an
Orthogonal Manner
To determine whether there is crosstalk between RNA hairpins
and non-cognate-binding proteins (e.g., MS2 RNA recruiting the
PCP protein), we expressed all three RNA hairpin designs (MS2,
PP7, and com) in yeast strains containing either the MCP, PCP,
or Com fusion proteins. We used a 73 tetO reporter to maximize
sensitivity for detecting any weak cross-activation. No significant
crosstalk was detected between mismatched pairs of scRNA
sequences andbindingproteins (Figure 2B). The strong activation
of reporter gene expression only with cognate scRNA- and RNA-
bindingproteinpairsdemonstrates thepotential for simultaneous,
independent regulation of multiple target genes.
Multivalent Recruitment to scRNAs
To tune the valency of effectors recruited to each gene target, we
introduced one, two, or three MS2 RNA hairpins to the 30 end of
the sgRNA. Surprisingly, reporter gene expression decreased
with increasing numbers of MS2 hairpins (Figure S1C). Northern
blot analysis indicated that steady-state RNA levels decreased
with two or three MS2 hairpins, suggesting that RNA expression
or stability is limiting for these constructs (Figure S2A).
To address the apparent stability problem of multi-hairpin
scRNAs, we constructed an alternative RNA design in which
double-stranded linkers were inserted between the two repeats
of the recruitment hairpins to enforce stable, local hairpin forma-
tion. These alternative designs produced stronger reporter gene
activation for both MS2 and PP7 modules relative to the analo-
gous single-hairpin scRNAs (Figure 2C). Northern blot analysis
of the 23 constructs with double-stranded linkers indicated
steady-state RNA levels comparable to single-hairpin scRNA
and unmodified sgRNA constructs (Figure S2A).
The strongest activation for a single scRNA construct was ob-
tained with a mixed hairpin construct containing two different
recruitment motifs for the MCP-VP64 effector protein (23 MS2
[WT + f6])—this construct contained one MS2 hairpin and a
second aptamer hairpin (f6) that had been selected to bind
to the MCP protein (Hirao et al., 1998–1999). Attempts to design
23 constructs with double-stranded linkers using the com RNA
module were unsuccessful, possibly because the cognate Com
protein binds to single-stranded RNA at the base of the com
hairpin (Hattman, 1999). RNA constructs with threeMS2 hairpins
connected by double-stranded linkers did not improve reporter
gene expression beyond that obtained with the 23MS2 scRNA.
Northern blot analysis suggests that these constructs are stablyCell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc. 341
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Figure 2. Multiple Orthogonal RNA-Binding Modules Can Be Used to Construct CRISPR Scaffolding RNAs
(A) scRNA constructs withMS2, PP7, or comRNA hairpins recruit their cognate RNA-binding proteins fused to VP64 to activate reporter gene expression in yeast.
A yeast strain with an unmodified sgRNA and the dCas9-VP64 fusion protein gives comparatively weaker reporter gene activation. The MS2 and PP7 RNA
hairpins bind at a dimer interface on their corresponding MCP- and PCP-binding partner proteins (Chao et al., 2008), potentially recruiting two VP64 effectors to
each RNA hairpin. The structure of the com RNA hairpin in complex with its binding protein has not been reported, but functional data suggest that a single Com
(legend continued on next page)
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expressed, so the lack of increased expressionmay be a result of
misfolding or steric constraints.
To develop a platform for recruitment of more complex pro-
tein assemblies, we designed a heterologous MS2-PP7 scRNA
sequenceusing the23double-stranded linker structure.Reporter
gene activation was substantially stronger in yeast cells with both
MCP-VP64 and PCP-VP64 effector proteins compared to cells
with only a single type of effector protein, indicating that distinct
RNA-bindingproteinscanbe recruited to the same target site (Fig-
ure 2D). This provides an effective approach to combinatorially
recruit multiple effectors for the logical control of target genes.
scRNAs Can Mediate Activation of Reporter and
Endogenous Genes in Human Cells
To test the efficacy of scRNA-based protein effector recruitment
in human cells, we ported the system from yeast to HEK293T
cells. The dCas9-binding hairpin of the sgRNA was modified
as described previously to improve activity in human cells (see
Extended Experimental Procedures) (Chen et al., 2013). In
HEK293T cells expressing dCas9, expression of an scRNA with
the corresponding VP64 fusion protein effector produced sub-
stantial activationof a73 tet-drivenGFP reportergene for all three
RNA-bindingmodules (Figure 3A), although there are somequan-
titative differences from the activity trends observed in yeast.
GFP activation with 13 MS2 and 13 PP7 scRNA constructs
was relatively weak compared to both corresponding multivalent
23 scRNA constructs and the dCas9-VP64 fusion protein.
To determine whether endogenous genes could be activated
by targeting a single site upstream of the coding sequence, we
designed ten target sequences for the C-X-C chemokine recep-
tor type 4 (CXCR4) (Table S3). CXCR4 expression is low in
HEK293T cells, and changes in gene expression can be quanti-
fied at the single-cell level by antibody staining. CXCR4 has pre-
viously been a target for CRISPR-based gene silencing in cell
types with high basal expression levels (Gilbert et al., 2013).
We used the divalent 23MS2 (WT + f6) scRNA design to recruit
the MCP-VP64 protein, and we observed increases in CXCR4
protein levels for nine of the ten target sites (Figure S3). For the
three strongest target sites, we compared CXCR4 activation
mediated by scRNA to that with dCas9-VP64 and observed
consistently stronger output with scRNA (Figure 3B).
scRNAs Recruit Chromatin Modifiers to Enhance Gene
Silencing in Human Cells
In human cells, CRISPRi-mediated repression is relatively
modest but can be enhanced by fusing dCas9 to the KRABmonomer protein binds at the base of the com RNA hairpin (Wulczyn and Kahm
expressed in yeast with dCas9 and a 13 tetO-VENUS reporter gene. Represent
(B) There is no significant crosstalk between mismatched pairs of scRNA seque
proteins were expressed in yeast with dCas9, using a 73 tetO-VENUS reporter ge
is on a log scale, and activity with cognate scRNA-binding protein pairs is signifi
(C) Multivalent recruitment with two RNA hairpins connected by a double-strand
hairpin recruitment domains. The 23MS2 (WT + f6) construct was designed with a
1999). This construct has two distinct sequences to recruit the same protein, whic
two identical hairpins are linked on the same RNA.
(D) A mixed MS2-PP7 scRNA constructed using the 23 double-stranded linker a
Fold change values in A–D are fluorescence levels relative to parent yeast strains
sequences are reported in Table S1.domain (Gilbert et al., 2013), a potent transcriptional repressor
that recruits chromatin modifiers to silence target genes (Groner
et al., 2010). To determine whether scRNAs could recruit KRAB
to enhance CRISPR-based gene silencing, we fused KRAB to
RNA-binding domains and designed scRNA constructs to target
an SV40 promoter driving GFP expression. We targeted one site
(P1) upstream of the transcriptional start site (TSS) and another
site (NT1) that overlaps the TSS. Recruitment of a Com-KRAB
fusion protein to either site by a com scRNA represses the
GFP reporter beyond that obtained by CRISPRi alone (there is
no significant CRISPRi effect at the P1 site upstream of the
TSS) (Figure 3C). The behavior of the KRAB domain recruited
by scRNA was similar to that obtained with a direct dCas9-
KRAB fusion protein. MCP-KRAB and PCP-KRAB fusion
proteins were ineffective at mediating repression, potentially
because MCP and PCP form dimers (Chao et al., 2008), which
could interfere with KRAB function.
Simultaneous ON/OFF Gene Regulation in Human Cells
The successful application of scRNA-mediated transcriptional
control in human cells opens the way toward simultaneous
ON/OFF gene regulatory switches mediated by orthogonal
RNA-binding proteins fused to transcriptional activators
(VP64) or repressors (KRAB). To test this possibility, we targeted
endogenous CXCR4 for activation with MCP-VP64 while
simultaneously targeting an additional endogenous gene for
repression with COM-KRAB in HEK293T cells. We selected
the b-1,4-N-acetyl-galactosaminyl transferase (B4GALNT1)
gene from a set of target sites previously validated for repres-
sion with the dCas9-KRAB fusion protein (Gilbert et al., 2014).
We observe simultaneous activation of CXCR4 and repression
of B4GALNT1 measured by RT-qPCR, and these changes in
gene expression are similar to that observed when single genes
were targeted (Figure 3D). Importantly, activation and repres-
sion are mediated by a single scRNA for each target gene.
Thus, this platform could, in principle, be used for large-
scale screening of pairwise combinations of genes that yield a
target phenotype when one gene is activated and the other is
repressed.
Harnessing scRNA Multigene ON/OFF Transcriptional
Programs to Redirect Metabolic Pathway Output in
Yeast
The complex multigene transcriptional programs that can
be generated using scRNAs and dCas9 have the potential to
rewire and control diverse cellular networks. One particularlyann, 1991). scRNA constructs and corresponding RNA-binding proteins were
ative flow cytometry data are presented in Figure S1.
nces and non-cognate binding proteins. scRNA constructs and RNA-binding
ne to detect any potential weak crosstalk betweenmismatched pairs. The y axis
cantly greater with the 73 tet reporter compared to the 13 reporter.
ed linker produces stronger reporter gene activation compared to single RNA
n aptamer sequence (f6) selected to bind to theMCP protein (Hirao et al., 1998–
hmay help to prevent misfolding between hairpin domains that can occur when
rchitecture recruits both MCP and PCP.
lacking scRNA. Values are median ± SD for at least three measurements. RNA
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Figure 3. CRISPR RNA Scaffold Recruit-
ment Can Activate or Repress Gene Expres-
sion in Human Cells
(A) scRNA constructs with MS2, PP7, or com RNA
hairpins recruit corresponding RNA-binding pro-
teins fused to VP64 to activate reporter gene
expression in HEK293T cells. scRNA- and RNA-
binding proteins were expressed in a cell line
with dCas9 and a TRE3G-EGFP reporter contain-
ing a 73 repeat of a tet operator site. For com-
parison, an unmodified sgRNA targeting the same
reporter gene was expressed in a cell line with the
dCas9-VP64 fusion protein. Representative flow
cytometry data are presented in Figure S3.
(B) The 23MS2 (WT + f6) scRNA construct recruits
MCP-VP64 to activate expression of endogenous
CXCR4 in HEK293T cells expressing dCas9.
Comparatively weak activation is observed in cells
with dCas9-VP64 and unmodified sgRNA. There is
no significant activation of CXCR4 in cells with
dCas9 and unmodified sgRNA. Similar effects
were observed at each of three individual target
sites located within 200 bases of the transcrip-
tional start site (TSS). Cell surface expression of
CXCR4 was measured by antibody staining.
(C) The com scRNA construct recruits Com-KRAB
to silence a SV40-driven EGFP reporter gene in
HEK293T cells expressing dCas9. At the P1 site,
upstream of the TSS, recruitment of dCas9 (i.e.,
CRISPRi) does not silence EGFP, but scRNA-
mediated KRAB recruitment does. At the NT1 site
overlapping the TSS, CRISPRi partially silences
EGFP, and scRNA-mediated KRAB recruitment
further enhances silencing. The P1 and NT1 target
sites were selected from a panel of sites examined
in a prior study (Gilbert et al., 2013).
Fold change values in A–C are fluorescence levels
relative to a parent cell line lacking scRNA. Values
are median ± SD for at least three measurements.
(D) scRNA constructs mediate simultaneous acti-
vation and repression at endogenous human
genes in HEK293T cells, measured by RT-qPCR.
A 23 MS2 (WT + f6) scRNA construct recruits
MCP-VP64 to activate CXCR4, and a 13 com
scRNA construct recruits COM-KRAB to silence
B4GALNT1.
Fold change values are gene expression levels
(mean ± SD) from two RT-qPCR measurements,
relative to negative control cell lines. The observed
change in CXCR4 mRNA level measured by RT-
qPCR corresponds to an increased protein level
(Figure S3D).interesting application is metabolic control. In biotechnology
production strains, there is often competition between pathways
required for cell growth versus production of the desired prod-
uct. In these cases, being able to facilely control the expression
of sets of metabolic enzymes, especially with bidirectional (ON/
OFF) control, is essential to optimizing new flux patterns and,
thereby, production of the desired product (Paddon et al.,
2013; Ro et al., 2006). There is a notable lack of approaches to
flexibly increase the expression of enzymes in a desired pathway
branch while simultaneously downregulating the expression of
enzymes in a competing branch.344 Cell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc.To test the ability of our scRNA programs to redirect metabolic
pathway outputs, we turned to the highly branched bacterial vi-
olacein biosynthetic pathway (Hoshino, 2011). The complete
five-gene pathway (VioABEDC) produces the violet pigment vio-
lacein, and branch points at the last two enzymatic steps (VioD
and VioC) can direct pathway output among four distinctly
colored products (Figure 4A). The five-gene pathway can be
reconstituted in yeast, and tuning the promoter strength for
expression of VioD and VioC redirects pathway output to
different products in a predictable manner (Lee et al., 2013).
The four product states are visually distinguishable in yeast
colonies and easily quantified by HPLC, making this pathway an
ideal model system to simultaneously tune expression levels of
multiple independent target genes to control functional output
states.
We designed a yeast reporter strain with two key control
points: the first (VioA) regulates total precursor flux into the
pathway, and the second regulates flow at the VioC/VioD branch
point. The VioBED genes are expressed by strong promoters,
and VioAC genes are under the control of weak promoters (Fig-
ure 4B and Table S4), so that turning VioA ON will drive flux into
the pathway, and flipping the ON/OFF expression states of VioC
and VioD will redirect the product output. The eight possible
pairwise ON/OFF combinations of these three genes lead to
five distinct output states: one state with complete pathway
output off and four alternative product states when the pathway
is on. To access all five states, we designed an scRNA program
to target VioA and VioCwith independent activators (23PP7 and
13 MS2, respectively) and to target VioD with CRISPRi-medi-
ated repression (Figure 4B and Table S2). Activation of VioA
routes pathway flux to the proviolacein product (PV) (Figure 4C).
Once VioA is activated, activation of VioC or repression of VioD
reroutes flux in a predictablemanner. Expressing all three scRNA
constructs simultaneously activates VioA and VioC and re-
presses VioD to route flux into the pathway and toward the deox-
yviolacein (DV) product. The scRNA/dCas9 platform flexibly and
efficiently generates each of the multigene transcriptional states
necessary to yield all possible metabolic outputs of the violacein
pathway.
Importantly, competition for a fixedpool of dCas9 is not limiting
when multiple scRNA constructs are expressed; we observe no
significant differences in scRNA-mediated effects at individual
gene targets when up to four scRNA constructs are expressed
(Figure S4). This result suggests that a large-scale scRNA pro-
gram can be implemented, as intracellular dCas9 concentration
is not a limiting factor, although it remains possible that effects
from limiting dCas9 will be observed with different expression
levels or if greater numbers of scRNAs are expressed.
dCas9 Acts as a Master Regulator to Execute
Expression Programs
The dCas9 protein is a central regulatory node in the execution of
scRNA-mediated gene expression programs, raising the possi-
bility that it could act as a single synthetic master regulator, con-
trolling expression levels for multiple downstream genes (Fig-
ure 5A). We designed a system in which expression of dCas9
controls a switch from a cell type that produces the PVmetabolic
product to one that produces DV. Expression of dCas9 was
controlled by an inducible pGal10-dCas9 construct. The starting
yeast strain contained the VioABED genes under the control of
strong promoters and VioC under the control of a weak promoter
(Table S4). We introduced a two-scRNA program to switch VioC/
VioD fromOFF/ON to ON/OFF, redirecting output from PV to DV.
When all components are present in yeast but Gal inducer is ab-
sent, PV is the dominant product. When the Gal inducer is pre-
sent, dCas9 is expressed to execute the simultaneous switch
of VioC ON and VioD OFF such that pathway output is routed
to DV (Figure 5B). Thus, multiple scRNAs can be regulated using
expression of the dCas9 protein as a single control point.DISCUSSION
CRISPR Toolkit Enables Construction of Complex
Regulatory Circuits
A wide range of CRISPR-related technologies have recently
emerged for editing and manipulating target genomes (Mali
et al., 2013b; Sander and Joung, 2014). A key advantage of these
tools is that they interface with core biological mechanisms, thus
allowing the system to be easily ported between different organ-
isms. Watson-Crick base-pairing rules specify target site selec-
tion, and synthetic effector proteins interface with conserved
features of the transcriptional machinery to control gene expres-
sion. Here, we have expanded the scope of the CRISPR toolkit
further by adding another basic feature of biological systems,
spatial organization mediated by scaffolding molecules, to link
functional effector domains to specific genomic target sites.
A modular scaffold RNA encodes, within a single molecule, the
information specifying the target site in the genome and the
particular regulatory function to be executed at that site. scRNAs
encode this information using a 50 20 base targeting sequence, a
common dCas9-binding domain, and a 30 protein recruitment
domain. Expression of multiple RNA scaffolds simultaneously
permits independent, programmable control of multiple genes
in parallel. Most simply, this approach provides a straightforward
method to implement simultaneous multigene ON/OFF regula-
tory switching programs.
scRNAs also allow straightforward fine-tuning of output levels
in a more analog fashion by altering the valency of effector pro-
teins recruited to an individual target site. Although not explored
here, an additional layer of expression control could come from
the choice of scRNA target site. In this work, we screened
several candidate target sites to identify those that produced
maximal output for further analysis (Figure S3 and Tables S2
and S3). To access a range of intermediate output levels, target
sites that are less effective could also be selected. More system-
atic screening approaches will provide general rules to select
target sites for varying output levels (Gilbert et al., 2014).
Finally, there are many different classes of protein effectors
and epigenetic modifiers that could be recruited via scRNAs
to produce different levels and types of gene activation or
repression. Qualitatively different regulatory strategies could
be implemented, such as regulators that can produce stable,
long-lived chromatin states that persist well after an input stim-
ulus is removed. Recent progress toward recruiting a library
of epigenetic modifiers with zinc finger proteins (Keung et al.,
2014) suggests that a similar range of functionality could be
achieved by recruitment via scRNAs. Thus, it may be possible
to construct even more nuanced and sophisticated gene
expression programs by using a variety of regulators with
CRISPR scRNAs and by recruiting these regulators in a combi-
natorial fashion.
These scRNA-encoded transcriptional programs have several
advantages that are lacking in other platforms. First, they are
easily programmable using Watson-Crick base pairing to target
desired endogenous loci in the genome. TAL effectors can be
used to generate complex programs, and these effectors can
produce larger effects on gene expression than CRISPR-based
approaches, but this requires the custom design ofmany distinctCell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc. 345
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Figure 5. The dCas9 Master Regulator Inducibly Executes scRNA-Encoded Programs
(A) dCas9 can act as a synthetic master regulator of scRNA-encoded circuits. We placed dCas9 under the control of an inducible Gal10 promoter. The yML017
yeast strain (Table S4) has VioABED genes strongly expressed (ON) and VioC weakly expressed (OFF). A 13 MS2 scRNA targets VioC for activation. An
unmodified sgRNA targets VioD for repression by CRISPRi.
(B) The presence of the master regulator dCas9 controls execution of the scRNA program. Yeast expressing a two-component scRNA program and MCP-VP64
were grown on agar plates in the presence or absence of galactose to control dCas9 expression. When the dCas9 master regulator is not present (-Gal), Vio
pathway gene expression remains in the basal state and pathway flux proceeds to the PV product. When dCas9 is present (+Gal), VioC switches ON, VioD
switches OFF, and pathway flux diverts to the DV product.TAL specificities (Kabadi and Gersbach, 2014). Second, scRNA
programs allow for distinct regulatory actions to take place at
each target locus. Though CRISPRi programs can be targeted
to many distinct sites in the genome, fusing or tethering a regu-
latory effector directly to the Cas9 protein allows only one type of
regulatory event (e.g., activation or repression) to take place at allFigure 4. Reprogramming the Output of a Branched Metabolic Pathwa
(A) Heterologous expression of the bacterial violacein biosynthesis pathway in y
zymatic step. Branch points at the last two enzymatic transformations catalyzed
(B) An scRNA program regulates three genes simultaneously to control flux into th
S4) has VioBED genes strongly expressed (ON) and VioAC genes weakly express
activation. An unmodified sgRNA targets VioD for repression by CRISPRi.
(C) scRNA programs flexibly redirect the output of the violacein pathway. The yM
formed with an empty parent vector (pRS316) or with a plasmid containing one, t
states (Table S6). Yeast strains were grown on SD –Ura agar plates. Product d
expected product of the engineered pathway. Quantitative values for changes
Figure S4B.targets. By tethering effectors to binding motifs in the scRNA,
which also encodes the target, we have created single RNAmol-
ecules that modularly specify both a target loci and regulatory
outcome in their sequence. Third, although multiple scRNAs
can be expressed to target many genes, they can still be
controlled by a single master regulatory event, the expressiony with a Three-Gene scRNA CRISPR ON/OFF Switch
east produces violacein from L-Trp with five enzymatic steps and one nonen-
by VioD and VioC produce four possible pathway outputs.
e pathway and to direct the choice of product. The yML025 yeast strain (Table
ed (OFF). A 23 PP7 scRNA targets VioA, and a 13MS2 scRNA targets VioC for
L025 yeast strain expressing dCas9, MCP-VP64, and PCP-VP64 was trans-
wo, or three scRNA constructs to route the pathway to all four product output
istribution was analyzed by HPLC. Stars on the chromatograms indicate the
in gene expression (by RT-qPCR) and product distributions are reported in
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Regulatory Programs
scRNAs can be combined with dCas9 to construct
designer transcriptional programs in which distinct
target genes can be simultaneously activated or
repressed or subject to other types of regulation.
Temporal control of the synthetic program can be
achieved by inducing the dCas9 protein as amaster
regulator. Alternative scRNA gene expression pro-
grams could be achieved in the same cell by har-
nessing orthogonal dCas9 proteins that recognize
their guide RNAs through distinct sequences (Esvelt
et al., 2013). Each orthogonal dCas9 protein could
control a distinct set of scRNAs, allowing indepen-
dent control over distinct gene expression pro-
grams. Each scRNA, in turn, allows independent
control at the level of an individual gene. Distinct
dCas9 proteins could be placed under the control of
differentextracellularsignalsor induciblepromoters.of the dCas9 protein, allowing temporal control over the entire
multigene program.
Orthogonal dCas9 proteins from other species (besides
S. pyogenes) can recognize guide RNAs with different dCas9-
binding modules (Esvelt et al., 2013) and thus can provide
another potential layer for modular control in CRISPR-engi-
neered transcriptional circuits that is complementary to the
scaffold RNAs explored here (Figure 6). For example, one could
create, in a single cell, alternative sets of scRNA programs, each
executed by an orthogonal dCas9 ortholog. In such a case, one
could switch between distinct programs by controlling the
expression of the dCas9 master regulators.
Applications: Reprogramming Complex Networks
Controlling Cell Function and Fate
scRNA-encoded transcriptional programs provide powerful
tools for manipulating complex cellular behaviors, such as differ-
entiation or metabolism. In metabolic engineering, microorgan-
isms can be engineered for biosynthesis by heterologous
expression of the desired metabolic pathway. Designing these
microbial production factories requires careful engineering
to prevent detrimental effects on host growth and metabolism,
to avoid buildup of toxic intermediates, and to coordinate
the expression of multiple genes to switch from growth to pro-
duction phase (Keasling, 2012). Often optimizing production
requires a coordinated increase in the expression of enzymes
that convert precursors into the desired product, as well as
simultaneous repression of enzymes that direct these precursors
toward alternative products. Because these alternative products
are often necessary for growth, optimized production requires
precise and coordinated temporal control. It is difficult to
construct complex programs of this type with only a handful of
well-characterized inducible promoters.
A CRISPR RNA-encoded gene expression program can
address these challenges by activating multiple target pathway
genes while simultaneously repressing branch points that divert
metabolites to cell growth. Execution of the program can be
controlled by a dCas9 master regulator that is induced at the
appropriate time. To avoid toxic intermediate buildup, expres-
sion levels of target pathway genes can be tuned to different348 Cell 160, 339–350, January 15, 2015 ª2015 Elsevier Inc.levels, using differential multivalent recruitment of activators,
to prevent bottlenecks. One potential limitation of the CRISPR-
mediated approach, however, is that metabolic flux is often
regulated by mechanisms that act posttranscriptionally (Daran-
Lapujade et al., 2007). Nevertheless, there are many situations
in which selectively altering transcription levels of pathway
enzymes can optimize metabolic flux (Ajikumar et al., 2010; Du
et al., 2012; Latimer et al., 2014; Yuan and Zhao, 2013).
To improve metabolite production, CRISPR RNA-based scaf-
folds could also be used as a rapid prototyping strategy to screen
gene expression programs that simultaneously alter the expres-
sion levels ofmultiplemetabolic enzymes. The regions of expres-
sion space that are identified by such screens could then be
customconstructedwith specific promoters to achieve finer con-
trol. CRISPR tools can also be combined with other approaches
to optimize metabolic networks. Global transcription machinery
engineering (gTME) screens mutations in general transcription
factors or coactivators to modify the expression of many genes
simultaneously (Alper et al., 2006). gTMEcouldbeused to identify
potential target genes for control by scRNA-encoded programs
and a dCas9 master regulator. Alternatively, a dCas9 master
regulator could be used to switch between global transcription
programs by activating and repressing modified general tran-
scription factors that elicit global changes in gene expression.
Finally, scRNA/CRISPR programs are easily transferable to
different hosts. Most metabolic engineering efforts use well-
characterized and genetically tractable hosts like E. coli or
S. cerevisiae, which offer many desirable industrial characteris-
tics. CRISPR-based tools to modify and regulate host genomes
may dramatically expand the space of microorganisms that can
be engineered for biosynthesis. Microbial strains or plants that
have desirable industrial characteristics or metabolic precursors
but lack good tools for genomemanipulationmay now be acces-
sible for engineering. CRISPR-based tools could also be used to
optimize target molecule production in the native host organism
for a desired pathway rather than in a heterologous host.
Another broad area of applications for customized expression
programs is in controlling cell fate decisions. During develop-
ment, master regulators specify cell fates by directly or indirectly
regulatingmultiple downstream target genes, and their presence
or absence can determine the outcome of a developmental line-
age (Chan and Kyba, 2013). A CRISPR-based multidirectional
ON/OFF switch program could provide a straightforward
method for genetic reprogramming by synthetically mimicking
the behavior of master regulators. scRNA programs could be
used to simultaneously activate and repress different master
regulators or to bypass master regulators and directly engage
the next layer of target genes to specify cell fates. scRNA pro-
grams could also be used to create customized hybrid cell fate
states that are not generated by natural master regulators but
that might still be useful in a therapeutic or research context. In
either scenario, the ability of dCas9 itself to act as a synthetic
master regulator will be a useful tool for controlling the timing
of differentiation. Synthetic control of cell fate reprogramming
could provide powerful new tools for regenerative medicine or
other cell-based therapeutics.
CRISPR scRNAs as Screening Tools for Biology
High-throughput synthetic lethal screens have proven extremely
powerful in analyzing complex biological systems and shedding
light on strategies for treating disease networks. Such screens,
however, whether they utilize siRNAs or CRISPRi sgRNAs, rely
on perturbing the expression of multiple genes in one direction
(usually repression). It is equally likely that we can learn new fea-
tures of networks by simultaneously activating and repressing
different combinations of genes. This is particularly true in cases
in which a particular cellular outcome requires both activation
of that response but also simultaneous inactivation of genes
involved in driving competing, alternative responses (Rais
et al., 2013). Themulti-directional but high-throughput regulation
that can be achieved with the scRNA/CRISPR platform is ideal
for this type of exploration.
EXPERIMENTAL PROCEDURES
scRNA Sequence Design
sgRNA sequences were extended to include hairpin sequences for MS2
(C5 variant) (Lowary andUhlenbeck, 1987), PP7 (Lim et al., 2001), or com (Hatt-
man, 1999). Sequences for linkers to the guide RNA and between hairpins
were generated by RNA Designer (Andronescu et al., 2004). Candidate
sequences were linked to the complete sgRNA sequence and evaluated in
NUPACK (Zadeh et al., 2011) to confirm that the extended hairpins were
compatible with sgRNA folding. Successful candidates were then evaluated
for function in yeast as described below. The 23MS2 (WT + f6) scRNA design
uses the SELEX f6 aptamer, whichwas selected to bind theMCP protein (Hirao
et al., 1998–1999). Sequences of the minimal sgRNA, extended scRNAs, and
RNA-binding modules are described in the Extended Experimental Proce-
dures and in Table S1.
Construct Design for CRISPR in Yeast
Mammalian codon-optimized S. pyogenes dCas9 (Qi et al., 2013) with three
C-terminal SV40 NLSs was expressed from a constitutive Tdh3 or inducible
Gal10 promoter. The dCas9-VP64 fusion protein was constructed with two
C-terminal SV40 NLSs, the VP64 domain (Beerli et al., 1998), and an additional
SV40 NLS. RNA-binding proteins MCP (DFG/V29I mutant) (Lim and Peabody,
1994), PCP (DFG mutant) (Chao et al., 2008), and Com (Hattman, 1999) were
expressed with an N-terminal SV40NLS and aC-terminal VP64 fusion domain.
All protein expression constructs were integrated in single copy into the yeast
genome. Complete descriptions of these constructs are provided in Table S5.
sgRNA constructs were expressed from the pRS316 CEN/ARS plasmid (ura3
marker) with the SNR52 promoter and SUP4 terminator (DiCarlo et al., 2013).sgRNA target sites are listed in Table S2. Twenty base guide sequences up-
stream of an appropriate PAM motif for S. pyogenes dCas9 (Qi et al., 2013)
were selected. For genes that had not been previously targeted for CRISPR-
based transcriptional regulation, we screened eight candidate sites upstream
of the gene and tested each site independently for the desired output
(Table S2). The target site with the strongest effect on output was used for sub-
sequent experiments. Methods for manipulation and analysis of yeast strains
are described in the Extended Experimental Procedures.
Construct Design for CRISPR in Human Cells
Plasmids for expression of S. pyogenes dCas9, dCas9 fusion proteins, and
sgRNA constructs were described previously (Gilbert et al., 2013). dCas9 con-
structs were expressed from an SFFV promoter with two C-terminal SV40
NLSs and a tagBFP. The dCas9-KRAB fusion protein was constructed with
a KRAB domain (Margolin et al., 1994) fused to the C terminus of the tagBFP.
The dCas9-VP64 fusion protein was constructed with two C-terminal SV40
NLSs, the VP64 domain, an additional SV40 NLS, and a tagBFP. sgRNA se-
quences were modified as described previously for expression in human cells
(see Extended Experimental Procedures) (Chen et al., 2013). sgRNAs were
expressed using a lentiviral U6-based expression vector derived from pSico
that expresses mCherry from a CMV promoter. To simultaneously express
sgRNAs and RNA-binding protein effectors, the mCherry cassette was modi-
fied to express the protein effector followed by an IRES and mCherry. RNA-
binding proteins (MCP, PCP, and Com) were expressed with an N-terminal
SV40 NLS and a C-terminal VP64 or KRAB fusion domain. Complete descrip-
tions of these constructs are provided in Table S7. sgRNA target site se-
quences are listed in Table S3. To simultaneously target two genes in human
cells, we designed a pSico-derived construct with a U6 promoter driving
expression of sgRNAs and a CMV promoter driving expression of a protein
effector followed by a p2A sequence and tagBFP (Table S7 and Figure S3C).
Methods for manipulation and analysis of human cells are described in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and eight tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2014.11.052.
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